Medicilon/MPI Preclinical Research-Shanghai has been recognized as an
accredited International Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC) facility. This accreditation further
underscores the company’s commitment to quality research. The AAALAC
initiative was led by Lijie Fu, PhD, Executive Vice President of
Operations, a national returnee with substantial industry, scientific
and CRO experience.
“We recognized that full AAALAC certification is essential for
establishing credibility within the industry.We understand and
appreciate the need for these standards, and have been diligently
working to achieve this goal.With our dedicated leadership and
this accreditation, we are now able to enhance our capabilities to
further meet the needs of our Sponsors,” says Bill Parfet, MBA,
Chairman of the Board of Medicilon/MPI Preclinical Research—Shanghai,
and Chairman and CEO of MPI Research.
Full AAALAC accreditation is a reflection of high standards,
accountability and a commitment to animal welfare. It is recognized as a
milestone and benchmark for responsible and ethical laboratory animal
care, and also sets standards for veterinary medical care, occupational
health and safety, and physical plant or HVAC standards that equal or
exceed many non-accredited Western institutions.
The company attributes the achievement of this certification to the dual
efforts of the dedicated scientific management team, led by Mingli Chen,
MD, MS, DABT, VP of Research, along with a multidisciplinary team
provided by one of the parent company’s, MPI Research. The team members
from MPI Research accepted long-term assignments in Shanghai to train
the local staff in Good Laboratory Practices (GLP) and AAALAC standards.
“We are fortunate to have such a knowledgeable and enthusiastic team
bringing our newly formed company up to the regulatory standards of the
industry.We pride ourselves in the excellence of work that we
produce and appreciate the steps that it takes to reach this level of
quality,” says Jintao Zhang, PhD, CEO of Medicilon/MPI Preclinical
Research- Shanghai. Dr. Zhang co-founded Medicilon Shanghai, the second
parent company of this joint venture, and served as its CEO in 2008.
Medicilon/MPI Preclinical Research-Shanghai provides global
pharmaceutical and biotechnology companies with high quality preclinical
drug discovery and development studies in an Asian facility that meet
worldwide regulatory standards.
For further information on Medicilon/MPI Preclinical Research-Shanghai,
visit medicilon-mpi.com.